These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1017849)

  • 1. [Assessment of the efficiency of vaccination against influenza (author's transl)].
    Ambrosch F; Wiedermann G
    Immun Infekt; 1976 Aug; 4(4):174-81. PubMed ID: 1017849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of an experiment of anti-influenza vaccination with a live and attenuated vaccine (author's transl)].
    Re MC; Callegari V; Dalpozzo S
    Ann Sclavo; 1978; 20(5):639-42. PubMed ID: 753131
    [No Abstract]   [Full Text] [Related]  

  • 3. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different influenza vaccine formulations and adjuvants for childhood influenza vaccination.
    Esposito S; Principi N
    Vaccine; 2011 Oct; 29(43):7535-41. PubMed ID: 21820478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of influenza vaccination in children: European perspective.
    Heikkinen T; Heinonen S
    Vaccine; 2011 Oct; 29(43):7529-34. PubMed ID: 21820481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza control in the 21st century: Optimizing protection of older adults.
    Monto AS; Ansaldi F; Aspinall R; McElhaney JE; Montaño LF; Nichol KL; Puig-Barberà J; Schmitt J; Stephenson I
    Vaccine; 2009 Aug; 27(37):5043-53. PubMed ID: 19559118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiological evaluation of the protection conferred by the Nivgrip vaccine against influenza caused by the A(H1N1) virus.
    Teodorovici G; Ivan A; Petrescu A; Mihail A; Cajal N
    Virologie; 1982; 33(4):279-82. PubMed ID: 7164342
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessment of the efficacy of influenza vaccines against natural challenge.
    Hobson D
    Dev Biol Stand; 1975; 28():285-94. PubMed ID: 1092575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaccination against influenza (author's transl)].
    De Rosa F
    Ann Sclavo; 1979; 21(6):836-42. PubMed ID: 554553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalent influenza vaccination with inactivated vaccines administered by nasal or oral route.
    Petrescu A; Mihail A; Popescu A; Cojiţă M; Sternberg I; Steiner N; Hondor C
    Virologie; 1976; 27(1):41-5. PubMed ID: 941402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing protection against influenza in children eligible for the vaccine for children program.
    Hull HF; O'Connor H
    Pediatr Infect Dis J; 2010 Oct; 29(10):910-4. PubMed ID: 20431426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Studies on live influenza virus vaccine. II. Evaluation of cold-adapted influenza A2 Hong Kong virus in volunteers (author's transl)].
    Mizutani H; Izuchi T
    Uirusu; 1973 Jun; 23(2):141-7. PubMed ID: 4808070
    [No Abstract]   [Full Text] [Related]  

  • 18. Universal influenza vaccination and live attenuated influenza vaccination of children.
    Glezen WP
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S104-9. PubMed ID: 18820568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM; Yi T; Ambrose CS
    Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological evaluation of the protection conferred by the Nivgrip vaccine against influenza caused by the A(H3N2) virus.
    Teodorovici G; Ivan A; Vieriu V; Duman F; Stenţer M; Frunzăreanu N; Petrescu A; Mihail A; Cajal N
    Virologie; 1984; 35(1):39-41. PubMed ID: 6710860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.